143 related articles for article (PubMed ID: 34907652)
21. A phase I/II study of the safety and efficacy of [
Wild D; Grønbæk H; Navalkissoor S; Haug A; Nicolas GP; Pais B; Ansquer C; Beauregard JM; McEwan A; Lassmann M; Pennestri D; Volteau M; Lenzo NP; Hicks RJ
Eur J Nucl Med Mol Imaging; 2023 Dec; 51(1):183-195. PubMed ID: 37721581
[TBL] [Abstract][Full Text] [Related]
22. Prospective observational study of
Garske-Román U; Sandström M; Fröss Baron K; Lundin L; Hellman P; Welin S; Johansson S; Khan T; Lundqvist H; Eriksson B; Sundin A; Granberg D
Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):970-988. PubMed ID: 29497803
[TBL] [Abstract][Full Text] [Related]
23. Long-Term Outcomes of Submaximal Activities of Peptide Receptor Radionuclide Therapy with
Minczeles NS; de Herder WW; Feelders RA; Verburg FA; Hofland J; Brabander T
J Nucl Med; 2023 Jan; 64(1):40-46. PubMed ID: 35680417
[TBL] [Abstract][Full Text] [Related]
24. Toxicity and Tolerability of
Khatami A; Sistani G; Sutherland DEK; DeBrabandere S; Reid RH; Laidley DT
Curr Radiopharm; 2022; 15(2):123-133. PubMed ID: 35135467
[TBL] [Abstract][Full Text] [Related]
25. Hematological Markers as Predictors of Treatment Outcomes with Lutetium 177 (
Satapathy S; Bhattacharya A; Sood A; Kapoor R; Gupta R; Sood A; Sharma P; Khosla D; Mittal BR
Cancer Biother Radiopharm; 2022 Feb; 37(1):23-29. PubMed ID: 34185573
[No Abstract] [Full Text] [Related]
26.
Strosberg JR; Caplin ME; Kunz PL; Ruszniewski PB; Bodei L; Hendifar A; Mittra E; Wolin EM; Yao JC; Pavel ME; Grande E; Van Cutsem E; Seregni E; Duarte H; Gericke G; Bartalotta A; Mariani MF; Demange A; Mutevelic S; Krenning EP;
Lancet Oncol; 2021 Dec; 22(12):1752-1763. PubMed ID: 34793718
[TBL] [Abstract][Full Text] [Related]
27. Dosimetric analysis of patients with gastro entero pancreatic neuroendocrine tumors (NETs) treated with PRCRT (peptide receptor chemo radionuclide therapy) using Lu-177 DOTATATE and capecitabine/temozolomide (CAP/TEM).
Thakral P; Sen I; Pant V; Gupta SK; Dureja S; Kumari J; Kumar S; Un P; Malasani V
Br J Radiol; 2018 Nov; 91(1091):20170172. PubMed ID: 30028180
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and tolerability of peptide receptor radionuclide therapy (PRRT) in advanced metastatic bronchial neuroendocrine tumours (NETs).
Mirvis E; Toumpanakis C; Mandair D; Gnanasegaran G; Caplin M; Navalkissoor S
Lung Cancer; 2020 Dec; 150():70-75. PubMed ID: 33075738
[TBL] [Abstract][Full Text] [Related]
29. 177Lu-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours: response to treatment and long-term survival update.
Demirci E; Kabasakal L; Toklu T; Ocak M; Şahin OE; Alan-Selcuk N; Araman A
Nucl Med Commun; 2018 Aug; 39(8):789-796. PubMed ID: 29912750
[TBL] [Abstract][Full Text] [Related]
30. Long-term results and tolerability of tandem peptide receptor radionuclide therapy with
Kunikowska J; Pawlak D; Bąk MI; Kos-Kudła B; Mikołajczak R; Królicki L
Ann Nucl Med; 2017 Jun; 31(5):347-356. PubMed ID: 28316066
[TBL] [Abstract][Full Text] [Related]
31. Safety and Efficacy of 177 Lu-DOTATATE in Neuroendocrine Tumor Patients With Extensive Bone Disease.
Alsadik S; Gnanasegaran G; Chen L; Quigley AM; Mandair D; Toumpanakis C; Caplin M; Navalkissoor S
Clin Nucl Med; 2023 Aug; 48(8):667-672. PubMed ID: 37167406
[TBL] [Abstract][Full Text] [Related]
32. Estimation of Absorbed Doses of Indigenously Produced "Direct-route" Lutetium-177-[
Kamaldeep ; Loharkar S; Das T; Basu S; Banerjee S
Cancer Biother Radiopharm; 2022 Apr; 37(3):214-225. PubMed ID: 34910891
[No Abstract] [Full Text] [Related]
33. Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE.
Parghane RV; Talole S; Prabhash K; Basu S
Clin Nucl Med; 2017 Jun; 42(6):428-435. PubMed ID: 28319500
[TBL] [Abstract][Full Text] [Related]
34. Peptide receptor radiotherapy re-treatment in patients with progressive neuroendocrine tumors: A systematic review and meta-analysis.
Strosberg J; Leeuwenkamp O; Siddiqui MK
Cancer Treat Rev; 2021 Feb; 93():102141. PubMed ID: 33418096
[TBL] [Abstract][Full Text] [Related]
35. Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course.
Bergsma H; Konijnenberg MW; Kam BL; Teunissen JJ; Kooij PP; de Herder WW; Franssen GJ; van Eijck CH; Krenning EP; Kwekkeboom DJ
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):453-63. PubMed ID: 26419852
[TBL] [Abstract][Full Text] [Related]
36. Single centre retrospective review of outcome of
Alsadik S; Gnanasegaran G; Chen L; Quigley AM; Mandair D; Toumpanakis C; Caplin M; Navalkissoor S
J Neuroendocrinol; 2022 Nov; 34(11):e13210. PubMed ID: 36399420
[TBL] [Abstract][Full Text] [Related]
37. 177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study.
Paganelli G; Sansovini M; Ambrosetti A; Severi S; Monti M; Scarpi E; Donati C; Ianniello A; Matteucci F; Amadori D
Eur J Nucl Med Mol Imaging; 2014 Oct; 41(10):1845-51. PubMed ID: 24615468
[TBL] [Abstract][Full Text] [Related]
38. Initial clinical evaluation of indigenous
Parghane RV; Mitra A; Bannore TU; Rakshit S; Banerjee S; Basu S
World J Nucl Med; 2021; 20(1):73-81. PubMed ID: 33850492
[No Abstract] [Full Text] [Related]
39. Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience.
Delpassand ES; Samarghandi A; Zamanian S; Wolin EM; Hamiditabar M; Espenan GD; Erion JL; O'Dorisio TM; Kvols LK; Simon J; Wolfangel R; Camp A; Krenning EP; Mojtahedi A
Pancreas; 2014 May; 43(4):518-25. PubMed ID: 24632546
[TBL] [Abstract][Full Text] [Related]
40. Lutetium oxodotreotide (
Smith-Palmer J; Leeuwenkamp OR; Virk J; Reed N
BMC Cancer; 2021 Jan; 21(1):10. PubMed ID: 33402120
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
